Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling

Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2024-12, Vol.255, p.116647, Article 116647
Hauptverfasser: Metscher, E., Meziyerh, S., Arends, E.J., Teng, Y.K.O., de Vries, A.P.J., Swen, J.J., Moes, D.J.A.R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 116647
container_title Journal of pharmaceutical and biomedical analysis
container_volume 255
creator Metscher, E.
Meziyerh, S.
Arends, E.J.
Teng, Y.K.O.
de Vries, A.P.J.
Swen, J.J.
Moes, D.J.A.R.
description Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice. To prevent organ rejection as well as infections, the prescribed immunosuppression needs to be well balanced. Dried blood spot (DBS) sampling has enabled development of remote voclosporin therapeutic drug monitoring. Here, we report on the development and analytical validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of voclosporin in dried blood spots. Method development was based on previously developed assays for the quantification of tacrolimus, everolimus, sirolimus, cyclosporin, mycophenolic acid, creatinine and iohexol in DBS and voclosporin in whole blood using LC-MS/MS. HemaXis™ volumetric blood spot devices were used for sample collection. The sample purification was based on the extraction of voclosporin from the DBS samples. Stable isotopically labeled voclosporin-D4 was used as an internal standard prior to sample purification. Bland Altman and Passing bablok analysis were performed for cross validation between whole blood and DBS samples. The method was successfully validated following the current ICH M10 guidelines. The dynamic range for the analyte was 10-600µg/L with an excellent mean coefficient of correlation of 0.9978. The within run and between run precision and accuracy were both within the acceptance criteria. The cross-validation against the whole blood method shows that the quantified voclosporin results are promising. This developed dried blood spot LC-MS/MS method was successfully validated and provides an easy, efficient workflow for therapeutic drug monitoring in kidney transplant patients or remote pharmacokinetic studies in lupus nephritis patients treated with voclosporin. •Highly sensitive LC-MS/MS method for voclosporin in dried blood spots•Bioanalytical method validation according to ICH M10 guidelines•Clinically tested in prospective study•First microsampling method for voclosporin
doi_str_mv 10.1016/j.jpba.2024.116647
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3149757346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708524006897</els_id><sourcerecordid>3149757346</sourcerecordid><originalsourceid>FETCH-LOGICAL-e1091-d0f758902ff827c68d70ee310714acd98cbcd89acff58aff90ea15fd06217de13</originalsourceid><addsrcrecordid>eNpdkU1LBDEMhosoun78AQ_So5dZm_nqFLzI-gkrHlTwVrptKl1mpmM7I3j0n9tl9SIEAuFJ8iYvIafA5sCgvljP18NKzXOWl3OAui75DplBw4ssr8u3XTJjvICMs6Y6IIcxrhljFYhynxwUgueiFjAj39fBoaGr1ntD4-BHulxkj88Xj8_0Y1L96KzTanS-p97ST69bn6DgepoiYK9aOgbVx6FNbCpoNzjsx0in6Pr31NBOHY7BaWr-74mqG9oEHZM9q9qIJ7_5iLze3rws7rPl093D4mqZITABmWGWV41gubVNznXdGM4QC2AcSqWNaPRKm0YobW3VKGsFQwWVNazOgRuE4oicb-cOwX9MGEfZuaixTcrRT1EWUApe8aKsE3r2i06rDo0cgutU-JJ_b0vA5RbAJPjTYZBRp7s1Gpd-MErjnQQmNy7Jtdy4JDcuya1LxQ9OToeL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149757346</pqid></control><display><type>article</type><title>Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Metscher, E. ; Meziyerh, S. ; Arends, E.J. ; Teng, Y.K.O. ; de Vries, A.P.J. ; Swen, J.J. ; Moes, D.J.A.R.</creator><creatorcontrib>Metscher, E. ; Meziyerh, S. ; Arends, E.J. ; Teng, Y.K.O. ; de Vries, A.P.J. ; Swen, J.J. ; Moes, D.J.A.R.</creatorcontrib><description>Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice. To prevent organ rejection as well as infections, the prescribed immunosuppression needs to be well balanced. Dried blood spot (DBS) sampling has enabled development of remote voclosporin therapeutic drug monitoring. Here, we report on the development and analytical validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of voclosporin in dried blood spots. Method development was based on previously developed assays for the quantification of tacrolimus, everolimus, sirolimus, cyclosporin, mycophenolic acid, creatinine and iohexol in DBS and voclosporin in whole blood using LC-MS/MS. HemaXis™ volumetric blood spot devices were used for sample collection. The sample purification was based on the extraction of voclosporin from the DBS samples. Stable isotopically labeled voclosporin-D4 was used as an internal standard prior to sample purification. Bland Altman and Passing bablok analysis were performed for cross validation between whole blood and DBS samples. The method was successfully validated following the current ICH M10 guidelines. The dynamic range for the analyte was 10-600µg/L with an excellent mean coefficient of correlation of 0.9978. The within run and between run precision and accuracy were both within the acceptance criteria. The cross-validation against the whole blood method shows that the quantified voclosporin results are promising. This developed dried blood spot LC-MS/MS method was successfully validated and provides an easy, efficient workflow for therapeutic drug monitoring in kidney transplant patients or remote pharmacokinetic studies in lupus nephritis patients treated with voclosporin. •Highly sensitive LC-MS/MS method for voclosporin in dried blood spots•Bioanalytical method validation according to ICH M10 guidelines•Clinically tested in prospective study•First microsampling method for voclosporin</description><identifier>ISSN: 0731-7085</identifier><identifier>ISSN: 1873-264X</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2024.116647</identifier><identifier>PMID: 39729691</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Dried blood spots ; LC-MS/MS ; Microsampling ; Therapeutic Drug Monitoring ; Voclosporin</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2024-12, Vol.255, p.116647, Article 116647</ispartof><rights>2024</rights><rights>Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39729691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Metscher, E.</creatorcontrib><creatorcontrib>Meziyerh, S.</creatorcontrib><creatorcontrib>Arends, E.J.</creatorcontrib><creatorcontrib>Teng, Y.K.O.</creatorcontrib><creatorcontrib>de Vries, A.P.J.</creatorcontrib><creatorcontrib>Swen, J.J.</creatorcontrib><creatorcontrib>Moes, D.J.A.R.</creatorcontrib><title>Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice. To prevent organ rejection as well as infections, the prescribed immunosuppression needs to be well balanced. Dried blood spot (DBS) sampling has enabled development of remote voclosporin therapeutic drug monitoring. Here, we report on the development and analytical validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of voclosporin in dried blood spots. Method development was based on previously developed assays for the quantification of tacrolimus, everolimus, sirolimus, cyclosporin, mycophenolic acid, creatinine and iohexol in DBS and voclosporin in whole blood using LC-MS/MS. HemaXis™ volumetric blood spot devices were used for sample collection. The sample purification was based on the extraction of voclosporin from the DBS samples. Stable isotopically labeled voclosporin-D4 was used as an internal standard prior to sample purification. Bland Altman and Passing bablok analysis were performed for cross validation between whole blood and DBS samples. The method was successfully validated following the current ICH M10 guidelines. The dynamic range for the analyte was 10-600µg/L with an excellent mean coefficient of correlation of 0.9978. The within run and between run precision and accuracy were both within the acceptance criteria. The cross-validation against the whole blood method shows that the quantified voclosporin results are promising. This developed dried blood spot LC-MS/MS method was successfully validated and provides an easy, efficient workflow for therapeutic drug monitoring in kidney transplant patients or remote pharmacokinetic studies in lupus nephritis patients treated with voclosporin. •Highly sensitive LC-MS/MS method for voclosporin in dried blood spots•Bioanalytical method validation according to ICH M10 guidelines•Clinically tested in prospective study•First microsampling method for voclosporin</description><subject>Dried blood spots</subject><subject>LC-MS/MS</subject><subject>Microsampling</subject><subject>Therapeutic Drug Monitoring</subject><subject>Voclosporin</subject><issn>0731-7085</issn><issn>1873-264X</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LBDEMhosoun78AQ_So5dZm_nqFLzI-gkrHlTwVrptKl1mpmM7I3j0n9tl9SIEAuFJ8iYvIafA5sCgvljP18NKzXOWl3OAui75DplBw4ssr8u3XTJjvICMs6Y6IIcxrhljFYhynxwUgueiFjAj39fBoaGr1ntD4-BHulxkj88Xj8_0Y1L96KzTanS-p97ST69bn6DgepoiYK9aOgbVx6FNbCpoNzjsx0in6Pr31NBOHY7BaWr-74mqG9oEHZM9q9qIJ7_5iLze3rws7rPl093D4mqZITABmWGWV41gubVNznXdGM4QC2AcSqWNaPRKm0YobW3VKGsFQwWVNazOgRuE4oicb-cOwX9MGEfZuaixTcrRT1EWUApe8aKsE3r2i06rDo0cgutU-JJ_b0vA5RbAJPjTYZBRp7s1Gpd-MErjnQQmNy7Jtdy4JDcuya1LxQ9OToeL</recordid><startdate>20241220</startdate><enddate>20241220</enddate><creator>Metscher, E.</creator><creator>Meziyerh, S.</creator><creator>Arends, E.J.</creator><creator>Teng, Y.K.O.</creator><creator>de Vries, A.P.J.</creator><creator>Swen, J.J.</creator><creator>Moes, D.J.A.R.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20241220</creationdate><title>Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling</title><author>Metscher, E. ; Meziyerh, S. ; Arends, E.J. ; Teng, Y.K.O. ; de Vries, A.P.J. ; Swen, J.J. ; Moes, D.J.A.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e1091-d0f758902ff827c68d70ee310714acd98cbcd89acff58aff90ea15fd06217de13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Dried blood spots</topic><topic>LC-MS/MS</topic><topic>Microsampling</topic><topic>Therapeutic Drug Monitoring</topic><topic>Voclosporin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Metscher, E.</creatorcontrib><creatorcontrib>Meziyerh, S.</creatorcontrib><creatorcontrib>Arends, E.J.</creatorcontrib><creatorcontrib>Teng, Y.K.O.</creatorcontrib><creatorcontrib>de Vries, A.P.J.</creatorcontrib><creatorcontrib>Swen, J.J.</creatorcontrib><creatorcontrib>Moes, D.J.A.R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Metscher, E.</au><au>Meziyerh, S.</au><au>Arends, E.J.</au><au>Teng, Y.K.O.</au><au>de Vries, A.P.J.</au><au>Swen, J.J.</au><au>Moes, D.J.A.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2024-12-20</date><risdate>2024</risdate><volume>255</volume><spage>116647</spage><pages>116647-</pages><artnum>116647</artnum><issn>0731-7085</issn><issn>1873-264X</issn><eissn>1873-264X</eissn><abstract>Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice. To prevent organ rejection as well as infections, the prescribed immunosuppression needs to be well balanced. Dried blood spot (DBS) sampling has enabled development of remote voclosporin therapeutic drug monitoring. Here, we report on the development and analytical validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of voclosporin in dried blood spots. Method development was based on previously developed assays for the quantification of tacrolimus, everolimus, sirolimus, cyclosporin, mycophenolic acid, creatinine and iohexol in DBS and voclosporin in whole blood using LC-MS/MS. HemaXis™ volumetric blood spot devices were used for sample collection. The sample purification was based on the extraction of voclosporin from the DBS samples. Stable isotopically labeled voclosporin-D4 was used as an internal standard prior to sample purification. Bland Altman and Passing bablok analysis were performed for cross validation between whole blood and DBS samples. The method was successfully validated following the current ICH M10 guidelines. The dynamic range for the analyte was 10-600µg/L with an excellent mean coefficient of correlation of 0.9978. The within run and between run precision and accuracy were both within the acceptance criteria. The cross-validation against the whole blood method shows that the quantified voclosporin results are promising. This developed dried blood spot LC-MS/MS method was successfully validated and provides an easy, efficient workflow for therapeutic drug monitoring in kidney transplant patients or remote pharmacokinetic studies in lupus nephritis patients treated with voclosporin. •Highly sensitive LC-MS/MS method for voclosporin in dried blood spots•Bioanalytical method validation according to ICH M10 guidelines•Clinically tested in prospective study•First microsampling method for voclosporin</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>39729691</pmid><doi>10.1016/j.jpba.2024.116647</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0731-7085
ispartof Journal of pharmaceutical and biomedical analysis, 2024-12, Vol.255, p.116647, Article 116647
issn 0731-7085
1873-264X
1873-264X
language eng
recordid cdi_proquest_miscellaneous_3149757346
source ScienceDirect Journals (5 years ago - present)
subjects Dried blood spots
LC-MS/MS
Microsampling
Therapeutic Drug Monitoring
Voclosporin
title Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A37%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dried%20blood%20spot%20LC-MS/MS%20quantification%20of%20voclosporin%20in%20renal%20transplant%20recipients%20using%20volumetric%20dried%20blood%20spot%20sampling&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Metscher,%20E.&rft.date=2024-12-20&rft.volume=255&rft.spage=116647&rft.pages=116647-&rft.artnum=116647&rft.issn=0731-7085&rft.eissn=1873-264X&rft_id=info:doi/10.1016/j.jpba.2024.116647&rft_dat=%3Cproquest_pubme%3E3149757346%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149757346&rft_id=info:pmid/39729691&rft_els_id=S0731708524006897&rfr_iscdi=true